Pyxis Oncology, Inc.
PYXS
$4.00
-$0.20-4.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 2.82M | -- | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 2.82M | -- | 0.00 | -- |
| Cost of Revenue | -- | -- | -- | 0.00 | -- |
| Gross Profit | -- | 2.82M | -- | 0.00 | -- |
| SG&A Expenses | 4.97M | 4.75M | 5.36M | 4.37M | 5.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.78M | 21.89M | 22.40M | 18.39M | 23.05M |
| Operating Income | -22.78M | -19.07M | -22.40M | -18.39M | -23.05M |
| Income Before Tax | -22.00M | -18.07M | -21.16M | -37.74M | -21.20M |
| Income Tax Expenses | -- | 283.00K | -- | -2.16M | -- |
| Earnings from Continuing Operations | -22.00M | -18.35M | -21.16M | -35.57M | -21.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.00M | -18.35M | -21.16M | -35.57M | -21.20M |
| EBIT | -22.78M | -19.07M | -22.40M | -18.39M | -23.05M |
| EBITDA | -22.25M | -18.53M | -21.85M | -17.84M | -22.32M |
| EPS Basic | -0.35 | -0.30 | -0.35 | -0.58 | -0.35 |
| Normalized Basic EPS | -0.22 | -0.18 | -0.22 | -0.17 | -0.22 |
| EPS Diluted | -0.35 | -0.30 | -0.35 | -0.58 | -0.35 |
| Normalized Diluted EPS | -0.22 | -0.18 | -0.22 | -0.17 | -0.22 |
| Average Basic Shares Outstanding | 62.56M | 61.92M | 61.05M | 61.25M | 60.72M |
| Average Diluted Shares Outstanding | 62.56M | 61.92M | 61.05M | 61.25M | 60.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |